Sina tip: This is a research report column, which is only an analyst's personal views and opinions on a stock, not a formal news report. Sina does not guarantee its authenticity and objectivity. All effective information about the stock is subject to the announcement of the Shanghai and Shenzhen Stock Exchanges. Investors are respectfully advised to pay attention to the risks.
The company (600079) is the first family planning concept listed company in the two cities. At present, it has formed an industrial pattern with medicine and reproductive health industries as the main industries, supplemented by education. In terms of family planning products, a pattern of reproductive health industry development has been formed, including condoms, medical latex, lotion, lubricants, reproductive health drugs, etc. The narcotic drugs of Yichang Humanwell Pharmaceutical Co., Ltd., a subsidiary, account for more than 25% of the national market, and Wuhan Humanwell Pharmaceutical Co., Ltd. has significantly improved its new product R&D and sales capacity.
Huaxia College of Wuhan University of Technology, which is jointly organized by the company and Wuhan University of Technology, has been established for three years and has won the praise of the Ministry of Education, Hubei Provincial Department of Education and the industry. This investment can provide a stable low risk return for the company in a long time.
In July this year, the company announced that it planned to issue 40 million to 70 million A-shares to domestic investors of no more than 10 specific targets, including major shareholders of the company, and raise about 380 million yuan to invest in medicine and education. This plan has been approved by the general meeting of shareholders. From the perspective of the recovery trend, after nearly four months of repeated shock and consolidation, the stock has recently built a bottom above the annual line, which is well prepared, and is expected to rebound significantly in the future, which can be focused on. (Shiji Investment)
Sina statement: The content of this article is purely the author's personal view, only for investors' reference, and does not constitute investment advice. Investors operate accordingly at their own risk.
